FDA has granted regular approval to alectinib (Alecensa) for treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, as detected by an FDA-approved test.
FDA has expanded the approval of Zelboraf (vemurafenib), a kinase inhibitor, to include the treatment of certain adult patients with Erdheim-Chester Disease, a rare blood cancer. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
FDA has granted regular approval to brentuximab vedotin (Adcetris) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy.
Seattle Genetics Inc. said it has submitted a supplemental Biologics License Application to FDA based on data from the phase III ECHELON-1 trial evaluating Adcetris (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.
John DiPersio, of Washington University School of Medicine in St. Louis, received a $6 million outstanding investigator award from NCI to support research aimed at improving therapies for leukemia.
John Hopkins researchers received a $5 million grant from the NCI to unite biologists, clinicians and engineers at the new Johns Hopkins Center for Cancer Target Discovery and Development.
Gad GetzChuan HeAviv RegevGad Getz, of the Broad Institute of MIT and Harvard, the Massachusetts General Hospital Cancer Center, and Harvard Medical School; Chuan He of the University of Chicago; and Aviv Regev of the Broad Institute have won the Paul Marks Prize for Cancer Research.
The Children's Neuroblastoma Cancer Foundation announced its support to advance research into a therapeutic strategy for high-risk neuroblastoma.
The Association of Community Cancer Centers presented the David King Community Clinical Scientist Award was presented to the Sanford Health Clinical Research Team from Sioux Falls.
The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has been named a 2017 Guardian of Excellence Award winner by Press Ganey for the second consecutive year.
